COVID-19 R&D support: US (FDA, BARDA, NIAID), Europe (EMA, EC), and globally (BioCentury resource hub)

Dear All,

And now for a change from our usually scheduled content! As you might expect, major agencies in the US (FDA, BARDA, NIAID) and Europe (EMA, EC, national agencies) are actively supporting the global R&D response to COVID-19. In addition, global consortia are appearing and BioCentury has provided both a newsletter on this as well as a well-organized resource hub (link), both free of charge.

In the US:


FDA have FDA have consolidated links to all their COVID-19 resources on to this webpage. The resources here include a Coronavirus Treatment Acceleration Program (CTAP, link) that seeks to use every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. Examples of actions via the CTAP program include 24-h turnaround on protocol review, 3-h turnaround on expanded access requests, and rapid triage of requests for guidance to appropriate FDA staff. In addition, FDA has guidance for trial conduct here.


BARDA have established a special portal on their countermeasures website to collect information about potential products or capabilities that could be utilized as part of this effort. BARDA’s interest includes both diagnostics and therapeutics. Applications submitted to their database are monitored and reviewed by BARDA and its interagency partners at NIH, CDC, DOD, and FDA.

If you think you may have a relevant product requiring support, you are encouraged to reach out to the agencies via the link below. The agencies will get back to you for follow-up as soon as possible. No specific timeline for response is stated: a patient attitude is likely appropriate in the face of what I hope is a substantial volume of submissions.

To submit data on your COVID-19 producthttps://www.medicalcountermeasures.gov/app/barda/coronavirus.aspx
General website link: https://medicalcountermeasures.gov/ 

In addition, you are encouraged to review recent changes to BARDA’s Broad Agency Announcement (Amendments 13 and 14), and DRIVe EZ-BAA (Special Instructions), which outline their current Areas of Interest reflecting a focus on SARS-CoV-2 countermeasures, via the following links.


NIAID has a range of resources for support of both basic research and candidate products — see the list below. If further clarification or assistance is required, please reach out to Ann Eakin (Ann.Eakin@nih.gov).

For those involved in animal care, AAVLD (the American Association of Veterinary Laboratory Diagnosticians) has a useful resource page here. The page covers SARS as well as COVID-19 and provides discussions of pets as fomites, testing of companion animals, and more.

In Europe:


EMA have a response team in place … read more details here: “The aim is to provide advice on regulatory requirements so that any promising medicinal product can be made available as rapidly as possible to patients, initially in the clinical trial setting and then, once authorised, on the market.” In addition, EMA has general guidance for sponsors here and GCP-focused guidance here.


The European Commission (EC) have a variety of programs underway. You can get a good start from this webpage. The Research and Innovation programs include support for Therapeutics, Diagnostics, and Vaccines. In particular, all the European Commission research and innovation calls on Covid-19 are here. Further, take note of these national efforts:

  • France has a Covid-19 Flash Call here 
  • Germany: BMBF has summarized its work-in-progress here and has a list of active calls here.
  • Spain: ISCIII has a call for Expressions of Interest here
  • UK: MRC has a COVID-19 Rapid Response Rolling Call here
  • [NEW on 20 Apr 2020] The online journal Science|Business has provided a table of additional calls within the EU. Go here to see it.

At a global level:


  • Global consortia are now starting to form. BioCentury has provided both a newsletter on this as well as a well-organized resource hub (link), both free of charge. BioCentury is not a sponsor or member of the consortium … the newsletter makes it clear that they fell into it via data-sharing discussions with several of the early members. The consortium is open to new members … see the newsletter for details.
  • [new on 21 Apr 2020] Superb webcast from 20 Apr 2020 featuring former FDA commissioners Scott Gottlieb and Mark McClellan is here. This 2-h webinar was an excellent survey of work underway both on the R&D side and on ways to collaborate on rapid evaluation of new products.
  • [new on 27 Apr 2020] IDSA (Infectious Diseases Society of America) has an excellent resource hub here. This hub is particularly noteworthy for carrying the society’s most current treatment guidelines.

Stay safe in these difficult times, All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Current funding opportunities:

  • Open now through 9 Apr 2020: NIAID Broad Agency Announcement (BAA) soliciting contract proposals for preclinical and clinical development of vaccines, therapeutic, and diagnostics for microbial pathogens. Go here for more.
  • Dates for the 2020 funding rounds for Novo REPAIR Impact Fund will be announced May 2020. Go here for current details.
  • 2020 funding rounds for CARB-X have not been announced.
  • The Global AMR R&D Hub’s dynamic dashboard (link) summarizes funders and projects by geography, stage, and more.

Upcoming meetings of interest to the AMR community:

  • 28 Apr 2020 (online, 17:00-18:30 CEST): GARDP REVIVE webinar. Title: “Inhaled antimicrobials: Do we get the drug to the bug?” Speaker: Harm A. W. M. Tiddens. Go here to register.
  • 9 Jul 2020 (online, 09:00-10:30 CEST): GARDP REVIVE webinar. Title: “The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study.” Speaker: Anand Anandkumar. Go here to register.
  • 17 Jul-2 Aug 2020 (Marine Biology Laboratory, Woods Hole, MA): Residential course entitled “Molecular Mycology: Current Approaches to Fungal Pathogenesis.” This 2-week intensive training program has run annually for many years and gets outstanding reviews. Go here for details.
  • 29 Jul-2 Aug 2020 (Philadelphia, PA): Small World Initiative Instructor Training Workshop – training for undergraduate professors and high school teachers in wet lab techniques, parallel curricula, pedagogical instruction to engage students in the hunt to find new antibiotics in soil. Go here to register.
  • 4 Aug 2020 (Silver Spring): FDA workshop entitled “Development Considerations of Antifungal Drugs to Address Unmet Medical Need.” Go here to register.
  • 5 Aug 2020 (Silver Spring): FDA workshop entitled “Developing Antifungal Drugs for the Treatment of Coccidioidomycosis (Valley Fever) Infection.” Go here to register.
  • 24-25 Aug 2020 (Basel): BEAM-, Novo REPAIR-, CARB-X-, DZIF-, ND4BB-, ENABLE-supported (among a long list!) Conference on Novel Antimicrobials and AMR Diagnostics. Details are here.
  • September 2020. University of Sheffield (UK). Applications are being taken for a new 1-year (full-time) or 2-year (part-time) Masters of Science course in Antimicrobial Resistance. The program runs annually from September and covers microbiology, clinical practice and policy. The course webpage is here.
  • 9-10 Sep 2020 (Washington, DC): US PACCARB public meeting. Go here for details.
  • 22-25 Sep 2020 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
  • 17-25 Oct 2020 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. Registration is here and is limited to 40 students.
  • 26-29 Oct 2020 (Rotterdam), Annual ESPID meeting (European Society for Pediatric ID, #38)
  • 10-13 Apr 2021 (Vienna): Annual ECCMID meeting (#31)
  • 20-24 June 2021 (Toronto): International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12). Go here for details.
  • 3-7 Jun 2021 (Anaheim), ASM Microbe 2021. Go here for details.

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

Consultancy: Sustainability framework for off-patent antibiotics // The Third Man

Dear All, I have just learned that the AMR Industry Alliance has posted an RFP for a consultant to support the work of its Access Working Group with applications for the RFP due 24 September 2021. The consultancy project focuses on the root causes of (or lack thereof!) supply chain resilience for off-patent antibiotics, including stockouts, shortages

Outstanding discussions of Pull, the NHS Pilot, and Antibiotic value

Dear All, The BEAM Alliance, along with its partners (CARB-X, the Novo REPAIR Impact Fund, the IMI AMR Accelerator, and the European Biotechnology Magazine) converted their annual AMR conference into a virtual event held 24-26 Aug 2021. As usual, it was excellent! I know we’re all really, REALLY tired of virtual meetings but the 2h/day x 3 day themed format worked well:

WHO-FAO-OIE-UNEP survey on a multi-stakeholder AMR platform

Dear All (this newsletter experiments with an Executive Summary/Details format; let me know what you think),  (Executive Summary)  As a further support for implementation of recommendations from the UN Interagency Coordination Group on Antimicrobial Resistance (IACG AMR), the Tripartite Plus (WHO-FAO-OIE-UNEP) are seeking to create a Partnership Platform that will “engage institutions representing states, markets and

“Astonishing mismatch”: Market potential of AMR tools vs. patient needs

Dear All, We have today an excellent report from the Global AMR R&D Hub entitled “Estimating Global Patient Needs and Market Potential for Priority Health Technologies Addressing Antimicrobial Resistance.” Both the bottom line and the key message of the report are clearly stated in the Preface: “… we hope that by showing the astonishing mismatch

Scroll to Top